pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
LianBio clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
CN HQ
2019 Founded
47 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
LianBio projects
5 ClinicalTrials.gov programs sponsored by LianBio.
LianBio has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
HRS-6213
Jian Li
Patients With Solid Tumors
1 trial -
High-Low Dose Radiotherapy
Jian Li
Nasopharyngeal Carcinoma (NPC)
1 trial -
Karelizumab combined with etoposide and cisplatin
Jian Li
Carcinoma
1 trial -
Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
Jian Li
COVID-19
1 trial -
SHR20004
Jian Li
Obesity
1 trial
Frequently asked questions
How many clinical projects does LianBio have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.